Gipharma was established in 2003 as spin off of Nycomed Amersham Sorin S.r.l. and is located in the North-Western Italian town of Saluggia (VC), a small town between Turin and Milan. Gipharma is authorized to produce and release for Europe small volumes parenterals, liquid and lyophilized (commercial products and IMP)
Since 2008 Gipharma is part of Advanced Accelerator Applications Group, a European leader in PET Radiopharmaceuticals and Radiometabolic Therapy.
Gipharma main business is represented by contract manufacturing of injectable drugs for pharma companies, among them GE Healthcare, Covidien, Synermed, IBI.
Furthermore it produces some proprietary products including generic SPECT radiopharmaceuticals, and a medical device for sterile separation and labeling of authologous white blood cells for Nuclear Medicine imaging.
Thanks to its long standing history of radiopharmaceuticals production (as Amersham and Sorin Biomedica) Gipharma gained a substantial experience in manufacturing of oxygen sensitive products.
The Company has also extended its manufacturing authorization to products containing API of human and animal tissue origin and to manufacturing of clinical trial batches.
Parallel to the production of freeze dried injectable products, Gipharma has developed a supply of GMP produced sterile vials in a large variety of formats and a GMP microbiological test service for PET centers throughout Europe.
Examples of sterile vials are:
Microbiological tests range from sterility tests, environmental controls, microorganism identification to endotoxins content determination.
As a third party manufacturer Gipharma also gained large experience in technology transfer, process validation and analytical test validation and can provide a flexible and fast service.
Gipharma has recently completed the installation of a second sterile filling/lyophilization line to increase its production capacity. Its freeze drying capacity is represented by two freeze driers (6.5 sqm shelves each) plus a smaller one used for freeze drying cycle developments.
Current production capacity is around 6 million vials (including lyofilisates, sterile vials and solutions)
With its increased production capacity and long standing experience, Gipharma is therefore able to offer a wide range of CMO services: